The results showed that the Taxus stent carried a higher rate of clotting starting six months after surgery. Boston Scientific reported the findings to FDA at the beginning of August. Despite the statistics, the company's spokesperson, Paul Donovan, stated that an increase in heart attacks or deaths hasn't been seen. Boston Scientific'sÂ main competitor in the stent market, Johnson & Johnson, hasn't observed a significant clotting risk in its product, Cypher. However, the overall risk of blood clots is low, and more studies probably should be conducted.